Matrix metalloproteinases and neuroinflammation in multiple sclerosis

Neuroscientist

Volumn 8, Issue 6, 2002, Pages 586-595

  Rosenberg, Gary A ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Blood brain barrier; Demyelination; Matrix metalloproteinase; Multiple sclerosis; Neuroinflammation; Stromelysin

Indexed keywords

MATRIX METALLOPROTEINASE; MYELIN; PROTEINASE;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; BASEMENT MEMBRANE; BLOOD; BLOOD BRAIN BARRIER; BLOOD VESSEL; BRAIN ISCHEMIA; BRAIN TUMOR; CELL MATURATION; CEREBROSPINAL FLUID; DEMYELINATION; DISEASE ASSOCIATION; ENCEPHALITIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLIOSIS; GUILLAIN BARRE SYNDROME; HYALINE DEGENERATION; IMMUNOLOGY; INFLAMMATION; MACROMOLECULE; MENINGITIS; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NERVE CELL; NERVE FIBER; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; WOUND HEALING;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; METALLOENDOPEPTIDASES; MULTIPLE SCLEROSIS;

EID: 0036892580     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858402238517     Document Type: Review

References (87)

1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. 1997. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406-15.
2. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, and others. 2001. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-32.
3. Benveniste EN. 1997. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis [Review]. J Mol Med 75:165-73.
4. Brosnan CF, Cammer W, Norton WT, Bloom BR. 1980. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 285:235-7.
5. Brown PD. 1998. Synthetic inhibitors of matrix metalloproteinases. In: Parks WC, Mecham RP, editors. Matrix Metalloproteinases. San Diego: Academic Press. p 243-62.
6. Cammer W, Bloom BR, Norton WT, Gordon S. 1978. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination. Proc Natl Acad Sci U S A 75:1554-8.
7. Caplan LR. 1995. Binswanger's disease-revisited [Review]. Neurology 45:626-33.
8. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. 1995. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201:223-6.
9. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, and others. 1997. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74:85-94.
10. Colton CA, Keri JE, Chen WT, Monsky WL. 1993. Protease production by cultured microglia: Substrate gel analysis and immobilized matrix degradation. J Neurosci Res 35:297-304.
11. Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. 1999. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 46:391-8.
12. Cuzner ML, Opdenakker G. 1999. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system [Review]. J Neuroimmunol 94:1-14.
13. Dawson JW. 1916. The histology of disseminated sclerosis. Trans R Soc Edin 50:517-25.
14. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den OJ, and others. 1999. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104:1507-15.
15. Ferguson B, Matyszak MK, Esiri MM, Perry VH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-9.
16. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. 2001. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 50:443-51.
17. Gay D, Esiri M. 1991. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 114:557-72.
18. Genain CP, Cannella B, Hauser SL, Raine CS. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-5.
19. Gijbels K, Galardy RE, Steinman L. 1994. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-82.
20. Gijbels K, Masure S, Carton H, Opdenakker G. 1992. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41:29-34.
21. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. 1993. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 36:432-40.
22. Giraudon P, Vernant JC, Confavreux C, Belin MF, Desgranges C. 1998. Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology 50(6):1920.
23. Gottschall PE, Yu X. 1995. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 64:1513-20.
24. Grossman RI, Gonzalez Scarano F, Atlas SW, Galetta S, Silberberg DH. 1986. Multiple sclerosis: Gadolinium enhancement in MR imaging. Radiology 161:721-5.
25. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. 1995. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120-6.
26. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. 1990. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40:1735-9.
27. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. 1999. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19:624-33.
28. Hewson AK, Smith T, Leonard JP, Cuzner ML. 1995. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflam Res 44:345-9.
29. Hughes PM, Wells GM, Clements JM, Gearing AJ, Redford EJ, Davies M, and others. 1998. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 121:481-94.
30. Ihara M, Tomimoto H, Kinoshita M, Oh J, Noda M, Wakita H, and others. 2001. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab 21:828-34.
31. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, and others. 1990. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189-204.
32. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, and others. 1990. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113:1477-89.
33. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, and others. 1998. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121:159-66.
34. Kieseier BC, Seifert T, Giovannoni G, Hartung HP. 1999. Matrix metalloproteinases in inflammatory demyelination: Targets for treatment [Review]. Neurology 53:20-5.
35. Kleiner DE, Stetler-Stevenson WG. 1994. Quantitative zymography: Detection of picogram quantities of gelatinases. Anal Biochem 218:325-9.
36. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. 1999. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122:191-7.
37. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, and others. 2001. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124:1734-42.
38. Leibowitz S, Kennedy L. 1972. Cerebral vascular permeability and cellular infiltration in experimental allergic encephalomyelitis. Immunology 22:859-69.
39. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, and others. 1998. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121:2327-34.
40. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. 2000. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: Association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis 31:80-4.
41. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. 1995. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154:4379-89.
42. Liedtke W, Cannella B, Mazzaccaro RJ, Clements JM, Miller KM, Wucherpfennig KW, and others. 1998. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 44:35-46.
43. Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, and others. 2001. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124:1743-53.
44. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-8.
45. Liuzzi GM, Mastroianni CM, Santacroce MP, Fanelli M, D'Agostino C, Vullo V, and others. 2000. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol 6:156-63.
46. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. 1999. Extracellular matrix degradation by metalloproteinases and central nervous system diseases [Review]. Mol Neurobiol 19:267-84.
47. Maeda A, Sobel RA. 1996. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55:300-9.
48. Matyszak MK, Perry VH. 1996. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 69:141-9.
49. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, and others. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J 16:2319-32.
50. Morita-Fujimura Y, Fujimura M, Gasche Y, Copin JC, Chan PH. 2000. Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury-induced brain trauma. J Cereb Blood Flow Metab 20:130-8.
51. Mun-Bryce S, Rosenberg GA. 1998a. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 274:R1203-11.
52. Mun-Bryce S, Rosenberg GA. 1998b. Matrix metalloproteinases in cerebrovascular disease [Review]. J Cereb Blood Flow Metab 18:1163-72.
53. Nagase H. 1997. Activation mechanisms of matrix metalloproteinases [Review]. Biol Chem 378:151-60.
54. Nagase H, Woessner JF Jr. 1999. Matrix metalloproteinases [Review]. J Biol Chem 274:21491-4.
55. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. 2000. Matrix metalloproteinases: Biologic activity and clinical implications [Review]. J Clin Oncol 18:1135-49.
56. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. 2001. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: Involvement of metalloproteinases. Brain 124:2203-14.
57. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis [Review]. N Engl J Med 343:938-52.
58. Okada Y, Nagase H, Harris ED. 1986. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem 261:14245-55.
59. Paterson PY. 1976. Experimental allergic encephalomyelitis: Role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc 35:2428-34.
60. Perry VH, Andersson PB. 1992. The inflammatory response in the CNS. Neuropathol Appl Neurobiol 18:454-9.
61. Persidsky Y, Limoges J, Rasmussen J, Zheng J, Gearing A, Gendelman HE. 2001. Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. J Neuroimmunol 114:57-68.
62. Putnam TJ, Adler A. 1937. Vascular architecture of the lesions of multiple sclerosis. Arch Neurol Psychiatry 38:1-15.
63. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP, and others. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-76.
64. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. 1994. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117:759-65.
65. Robert AM, Godeau G. 1974. Action of proteolytic and glycolytic enzymes on the permeability of the blood-brain barrier. Biomedicine 21:36-9.
66. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. 1998. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020-30.
67. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, and others. 2001. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: Activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893:104-12.
68. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. 1996. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology 46:1626-32.
69. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG. 1994. Injury-induced 92-kDa gelatinase and urokinase expression in rat brain. Lab Invest 71:417-22.
70. Rosenberg GA, Estrada EY, Dencoff JE. 1998. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189-95.
71. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. 1995. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window. Brain Res 703:151-5.
72. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. 1992. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576:203-7.
73. Rosenberg GA, Mun-Bryce S, Wesley M, Kornfeld M. 1990. Collagenase-induced intracerebral hemorrhage in rats. Stroke 21:801-7.
74. Rosenberg GA, Navratil M, Barone F, Feuerstein G. 1996, Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360-6.
75. Rosenberg GA, Sullivan N, Esiri MM. 2001. White matter damage is assoiciated with matrix metalloproteinases in vascular dementia. Stroke 32:1162-8.
76. Sears ES, Tindall RS, Zarnow H. 1978. Active multiple sclerosis. Enhanced computerized tomographic imaging of lesions and the effect of corticosteroids. Arch Neurol 35:426-34.
77. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. 2000. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 7:281-9.
78. Selmaj K, Raine CS, Cannella B, Brosnan CF. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-54.
79. Sharief MK, Hentges R. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-72.
80. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, and others. 1996. Interferon beta-lb decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neurol 40:853-63.
81. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, and others. 1999. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-lb treatment in relapsing-remitting MS [see Comments]. Neurology 53:1402-8.
82. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, and others. 1999. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53:1397-401.
83. Wisniewski HM, Bloom BR. 1975. Primary demyelination as a non-specific consequence of a cell-mediated immune reaction. J Exp Med 141:346-59.
84. Yang JQ, Zhao W, Duan H, Robbins ME, Buettner GR, Oberley LW, and others. 2001. v-Ha-RaS oncogene upregulates the 92-kDa type IV collagenase (MMP-9) gene by increasing cellular superoxide production and activating NF-kappaB. Free Radic Biol Med 31:520-9.
85. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-11.
86. Yurchenco PD, Schittny JC. 1990. Molecular architecture of basement membranes [Review]. FASEB J 4:1577-90.
87. Zhang WW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie JX, and others. 1994. Structural and vasoactive factors influencing intracerebral arterioles in cases of vascular dementia and other cerebrovascular disease: A review. Immunohistochemical studies on expression of collagens, basal lamina components and endothelin-1 [Review]. Dementia 5:153-62.